NRX Pharmaceuticals (NRXP) Total Debt (2018 - 2025)
NRX Pharmaceuticals' (NRXP) quarterly Total Debt came in at $152000.0 in Q3 2025, down 76.03% year-on-year from $634000.0 in Q3 2024, and down 59.79% on a QoQ basis from $378000.0 in Q2 2025.
NRX Pharmaceuticals (NRXP) Total Debt (2018 - 2025) Analysis & Trends
NRX Pharmaceuticals (NRXP) has 7 years of Total Debt data on file, last reported at $152000.0 in Q3 2025.
- On a quarterly basis, Total Debt fell 76.03% year-over-year to $152000.0 in Q3 2025; TTM through Sep 2025 was $152000.0, a 76.03% decrease from a year earlier, with the FY2024 full-year figure at $320000.0, changed N/A from the prior year.
- Total Debt for Q3 2025 stood at $152000.0, down from $378000.0 in the prior quarter.
- Over the last five years, Total Debt for NRXP reached as high as $26.3 million in Q3 2021 and fell as low as $152000.0 in Q3 2025.
- Historically, Total Debt has averaged $6.3 million across 4 years, with a median of $1.2 million in 2021.
- Across the five-year window, Total Debt soared 3367.17% in 2021 and plunged 76.03% in 2025, its largest moves.
- Year by year, Total Debt stood at $4.6 million in 2021, then plunged by 45.9% to $2.5 million in 2022, then sank by 87.09% to $320000.0 in 2024, then tumbled by 52.5% to $152000.0 in 2025.
- Per Business Quant data, the three most recent Total Debt figures were $152000.0 in Q3 2025, $378000.0 in Q2 2025, and $320000.0 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,583.17 Bn | 67,582.89 Bn | - | - |
| 2 | Nanobiotix | 1,941.00 Bn | 1,940.94 Bn | - | 110.96 Mn |
| 3 | Akari Therapeutics | 1,132.35 Bn | 1,132.35 Bn | - | - |
| 4 | BeOne Medicines | 473.62 Bn | 468.83 Bn | 1.35 Bn | 959.06 Mn |
| 5 | Vertex Pharmaceuticals | 123.20 Bn | 115.95 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 70.05 Bn | 61.30 Bn | 3.31 Bn | 1.99 Bn |
| 7 | Belite Bio | 62.96 Bn | 62.96 Bn | - | - |
| 8 | Argenx Se | 56.57 Bn | 51.38 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.59 Bn | 34.58 Bn | 959.66 Mn | - |
| 10 | NRX Pharmaceuticals | 121.86 Mn | 115.16 Mn | 437,000.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 152,000.00 |
| Jun 30, 2025 | 378,000.00 |
| Dec 31, 2024 | 320,000.00 |
| Sep 30, 2024 | 634,000.00 |
| Jun 30, 2024 | 943,000.00 |
| Mar 31, 2022 | 2.48 Mn |
| Dec 31, 2021 | 4.58 Mn |
| Sep 30, 2021 | 26.28 Mn |
| Jun 30, 2021 | 25.87 Mn |
| Mar 31, 2021 | 1.38 Mn |
| Sep 30, 2020 | 758,060.00 |
| Jun 30, 2020 | 1.67 Mn |
| Mar 31, 2020 | 1.63 Mn |
| Dec 31, 2019 | 416,141.00 |
| Sep 30, 2019 | 327,198.00 |
| Jun 30, 2019 | 1.38 Mn |
| Mar 31, 2019 | 1.49 Mn |
| Dec 31, 2018 | 690,000.00 |